A STATE DEFINED BY ITS DISEASE BURDEN.

Any serious account of cancer care at the Royal Brisbane and Women’s Hospital must begin not with the institution, but with the state it serves — because Queensland’s relationship with cancer is not incidental. It is geographical, climatic, cultural, and deeply embedded in the texture of everyday life. rbwh.queensland represents, in civic namespace terms, a permanent address for one of Australia’s most consequential public health institutions — one whose cancer services exist not simply as a medical specialty but as a structural response to a population-level condition that shapes Queensland more profoundly than almost any other chronic disease.

Australia has the highest rate of skin cancer in the world, and Queensland, according to Queensland Health’s own published data, has the highest rate in Australia. That distinction is not a point of pride; it is a mandate. The standardised incidence rate for all cancers was, as of 2020, more than twelve percent higher in Queensland than the national average, with melanoma as the principal driver of that difference. The Skin Cancer Prevention Queensland collaborative has noted that Queensland’s melanoma incidence rates are approximately forty percent higher than the national rate, with more than 3,600 Queenslanders diagnosed with melanoma each year, and over 350,000 non-melanoma skin cancers treated annually across the state. In 2023 and 2024, Queensland hospitals recorded more than 37,000 episodes of care for skin cancer alone, and in 2022, 4,249 Queenslanders were diagnosed with melanoma — the most serious form of the disease.

These numbers do not remain abstractions. They flow through the public health system and accumulate, with intensity, at the quaternary referral end of the clinical spectrum — at Herston, in the wards and treatment suites of the Royal Brisbane and Women’s Hospital. To understand what RBWH does in oncology is to understand what it means to run a public cancer service in the most UV-exposed corner of a continent already defined by its skin cancer burden. The epidemiology is the context. The institution is the response.

QUEENSLAND'S LARGEST PUBLIC ONCOLOGY SERVICE.

The Cancer Care Service at Royal Brisbane and Women’s Hospital is, according to the Metro North Health Service District and the RBWH Foundation, the largest cancer care service in Queensland. That designation carries weight in a state with a geographically dispersed population and a public hospital system that must serve not only greater Brisbane, but communities across the breadth of the state and beyond its borders.

RBWH’s Cancer Care Service draws patients from Queensland, northern New South Wales, and the Northern Territory — a catchment that reflects its standing as a quaternary referral centre rather than simply a large regional facility. In 2023, the service managed 89,425 visits, a figure that speaks to scale but understates complexity: these are not routine consultations but oncology engagements requiring specialist teams, coordinated multidisciplinary input, and — in many cases — access to therapies unavailable anywhere else in the state.

The services housed within the Cancer Care division are broad. Outpatient and inpatient treatment streams cover medical oncology, radiation oncology, haematology, bone marrow transplantation, haemophilia care, and palliative and supportive care. The service is located primarily in the Joyce Tweddell Building on the Herston campus, where Ward 5C — the Haematology and Bone Marrow Transplant unit — operates alongside Radiation Specialty Suites, and where Ward 6A South manages chemotherapy and radiation therapy for patients with solid tumours including lung, breast, and bowel cancers. The physical arrangement of the Cancer Care Service across the Joyce Tweddell and Ned Hanlon Buildings reflects decades of institutional accretion, of a service that has grown not according to an abstract plan but in response to accumulating clinical need.

What distinguishes RBWH’s oncology service from other large public hospitals is not simply its size but its scope. In 2022, it was recognised as one of the top hundred cancer care centres worldwide — one of only three such facilities in Australia to receive that designation. That recognition, drawn from international assessment of outcomes, research activity, and clinical capability, placed the service in a cohort defined not by geography but by excellence.

HAEMATOLOGY, BONE MARROW TRANSPLANT, AND CELLULAR THERAPY.

Within the broader Cancer Care division, haematology and bone marrow transplantation represent a particular concentration of specialist capability. The Haematology and Bone Marrow Transplant service at RBWH holds international accreditation with FACT — the Foundation for the Accreditation of Cellular Therapies — and, according to Metro North Health’s published documentation, was the first bone marrow transplant unit in Australia to hold FACT accreditation. This places the service within a global framework of quality assurance that goes beyond the domestic regulatory environment and signals a deliberate alignment with international standards.

The research orientation of the haematology unit has shaped both its clinical profile and its treatment capabilities. The department participates in a range of local investigator-driven studies, collaborative study group partnerships including the Australasian Leukaemia and Lymphoma Group, and large international trials. There is ongoing collaboration between departmental clinical staff and the QIMR Berghofer Medical Research Institute — a partnership formalised through the hospital’s broader research infrastructure and focused on developing and participating in translational research programs that move laboratory findings into clinical application.

Among the most significant of the service’s current capabilities is its work in CAR-T cell therapy. The RBWH Cancer Care Service is one of only six adult centres in Australia accredited for CAR-T collection and administration, and the only such centre in Queensland. Chimeric Antigen Receptor T-cell therapy represents one of the more consequential advances in haematological oncology in recent decades — a form of personalised cellular therapy that reprograms a patient’s own immune cells to identify and attack cancer. What is especially notable about RBWH’s CAR-T program is that it does not rely solely on commercially manufactured therapies produced overseas. As documented in published interviews with the haematology unit’s clinical staff, the hospital has local expertise to produce CAR-T cells on site, manufactured as part of research programs within the facility itself, in Queensland. This gives the service a capacity for research-embedded clinical practice that is unusual even by national standards.

The research program associated with CAR-T at RBWH includes studies examining how the immune system functions after cellular therapy, investigations into the neurocognitive effects of treatment — both short-term and long-term — and patient-reported outcome studies designed to capture the lived experience of undergoing this form of treatment. The haematology department also operates a multifaceted program of bone marrow transplant research examining complications including post-transplant infection, disease relapse, and Graft Versus Host disease — the full set of challenges that make blood cancer treatment so demanding for patients and clinicians alike.

RADIATION ONCOLOGY AND THE FULL-SPECTRUM MANDATE.

Radiation oncology has long been a foundational pillar of the RBWH Cancer Care Service. Radiation therapy is, according to Queensland Cancer Centre planning documents, the primary method of cancer treatment for approximately fifty percent of all cancer patients — a statistic that underscores the weight this specialty carries within any comprehensive oncology service.

The radiation oncology program at RBWH treats patients across a wide range of tumour sites, operating from dedicated outpatient and inpatient facilities within the Joyce Tweddell Building. The program is integrated with the broader medical oncology and haematology streams through the multidisciplinary team model that characterises modern tertiary oncology practice, where no treatment decision is made in isolation but through the accumulated clinical judgement of specialists drawn from multiple disciplines.

It is the forthcoming Queensland Cancer Centre — a purpose-built facility to be constructed within the Herston Health Precinct adjacent to and expanding upon the existing RBWH campus — that will carry radiation oncology capability into a new register. According to Queensland Government ministerial announcements and Infrastructure Pipeline reporting, the Queensland Cancer Centre will be one of only two facilities in Australia to offer proton beam therapy: a specialised form of radiation therapy that can more precisely target cancers near vital and vulnerable organs, reducing collateral damage to surrounding healthy tissue. This matters especially for children undergoing cancer treatment, where the reduction of long-term radiation effects on developing tissues is a clinical priority of the highest order.

The Queensland Cancer Centre is planned as a 150-bed facility, with completion projected for 2028. It has been described in official Queensland Government statements as set to be the only cancer care facility in the country offering the full spectrum of cancer services in one place — a consolidation of what currently exists in distributed form across the RBWH campus into an integrated, purpose-built environment designed for a level of demand that will only grow. Combined Queensland State Government and Australian Federal Government investment in the centre exceeds $1.1 billion, with the Queensland Government committing $750 million and the Albanese Government contributing a further $375 million. The Herston Health Precinct’s own planning documents describe the facility as a centre of excellence that will enable greater research generation and its translation into local health solutions — the kind of institutional ambition that, when backed by capital of this order, has a reasonable chance of being realised.

ADOLESCENT AND YOUNG ADULT CANCER CARE.

One dimension of the RBWH Cancer Care Service that deserves separate attention is its provision for adolescents and young adults — a cohort whose oncological needs have historically sat awkwardly between the paediatric and adult care systems, too old for children’s hospitals and often poorly served by standard adult oncology wards.

The You Can Centre at RBWH — developed with the support of the Sony Foundation and funded in part through a $1.8 million donation from that organisation alongside Queensland Government commitment — opened as Queensland’s first public specialised adolescent and young adult cancer centre. It was designed for patients aged fifteen to twenty-five years and functions not only as a clinical space but as a social environment attuned to the particular psychological and developmental pressures that cancer diagnosis imposes on young people. The age-appropriateness of the environment — its design, its technology, its social infrastructure — reflects a growing recognition that the experience of cancer treatment is not uniform across age groups, and that care environments themselves carry therapeutic or counter-therapeutic weight.

Melanoma is the most commonly diagnosed cancer among Australians aged fifteen to thirty-nine years, and Queensland’s epidemiological profile makes this burden particularly acute in this state. The existence of a dedicated young adult facility at Queensland’s largest public oncology service is therefore not incidental — it is a direct institutional response to a disease pattern that strikes hardest at the youngest working-age Queenslanders.

RESEARCH, CLINICAL TRIALS, AND THE QIMR BERGHOFER PARTNERSHIP.

The Cancer Care Service at RBWH does not treat research as supplementary to its clinical function. Per the hospital’s own Cancer Care research reports, research is considered “core business” within the division — the vehicle through which progressive treatment is made available to patients who might otherwise wait years for emerging therapies to filter through approval processes and into mainstream clinical practice.

The Cancer Care research team encompasses allied health professions, the Cancer Nursing Professorial Precinct, medical oncology, radiation oncology, haematology including the Haemophilia Centre, and the Bone Marrow Transplant unit. This breadth reflects the multidisciplinary character of modern oncology, in which advances in nursing, pharmacy, physiotherapy, nutrition, and social support are as clinically significant as new drug protocols or surgical techniques.

The hospital’s partnership with QIMR Berghofer Medical Research Institute is central to the research ecosystem. QIMR Berghofer — itself one of Australia’s foremost medical research institutions — is located adjacent to the RBWH campus within the Herston Health Precinct, creating a physical proximity between laboratory discovery and clinical application that is relatively rare. As documented in the hospital’s research report publications and clinical trials registries, this collaboration provides the haematology and oncology departments with improved capacity to develop and participate in translational research programs, moving findings from bench to bedside with a speed that more geographically separated institutions cannot match.

The Herston Imaging Research Facility — co-located at the hospital — further deepens the research capability by enabling advanced neuroimaging and PET/MRI research in oncology, neurology, psychiatry, and dementia. For cancer care specifically, imaging innovation is not peripheral: it informs staging, guides treatment planning, and enables the monitoring of response that shapes clinical decision-making throughout a patient’s oncology journey.

PALLIATIVE AND SUPPORTIVE CARE AS INSTITUTIONAL COMMITMENT.

Cancer care does not end with treatment, and a meaningful account of RBWH’s oncology function cannot ignore what happens when treatment reaches its limits — or when the goal of care shifts from cure to comfort. The hospital’s Palliative and Supportive Care service, described in official Metro North health documentation and research publications, is an integrated component of the cancer care division, not an afterthought.

The Centre for Palliative Care Research and Education — established as a Queensland Health initiative in collaboration with RBWH — focuses on enhancing palliative care through statewide education programs, annual research conferences, and studies on symptom management and end-of-life care. Its existence as a research-oriented centre, rather than simply a clinical one, reflects a broader understanding that good end-of-life care is not simply a matter of medication management but of evidence-based practice developed through rigorous inquiry.

This integration of palliative care within the cancer care ecosystem is significant in a state where cancer affects tens of thousands of families each year. The Chief Health Officer Queensland’s reporting notes that five-year cancer survival for all cancers combined increased from 46.9 percent in the period 1991–1995 to 63.7 percent in 2016–2020 — a thirty-five percent improvement that represents genuine clinical progress. But improving survival rates also mean that more people live longer with cancer as a chronic condition, requiring sustained supportive care across extended treatment horizons. The service model at RBWH accounts for this reality.

The RBWH homepage has noted the hospital’s unveiling of a memorial to honour Maureen Kirk, a pioneering Aboriginal and Torres Strait Islander cancer support worker — a small but meaningful acknowledgement that the patient population served by Queensland’s largest public oncology service includes communities for whom cancer care must be culturally safe as well as clinically effective. The recognition of Kirk’s contribution speaks to an institutional awareness that the social and cultural dimensions of cancer care are not separable from its technical dimensions.

A PERMANENT CIVIC ADDRESS FOR AN ENDURING PUBLIC MANDATE.

The cancer burden Queensland carries is, in significant measure, a function of where Queensland sits on the earth — its latitude, its climate, its outdoor culture, its cumulative exposure to ultraviolet radiation of an intensity unmatched in most of the inhabited world. The Queensland Government’s own health reporting acknowledges that the standardised melanoma incidence rate in Queensland increased by more than sixty percent between 1982 and 2019. These are not numbers that can be argued away by public health campaigns alone, though campaigns matter. They are structural features of life in this state, and they require structural responses at the clinical level.

The Royal Brisbane and Women’s Hospital’s Cancer Care Service is that structural response in its most concentrated institutional form. From its accredited haematology and bone marrow transplant program — the first of its kind in Australia to achieve FACT re-accreditation — to its position as one of only six adult CAR-T centres nationally, from its dedicated young adult cancer facility to its role as the anchor institution for the forthcoming Queensland Cancer Centre, RBWH at Herston represents the point at which Queensland’s public obligation to its cancer patients is made most visibly real. It is a service that treats patients from three jurisdictions, that hosts research capable of influencing oncology practice internationally, and that is preparing, through the construction of new infrastructure, to do significantly more.

Institutions of this character — ones that accumulate decades of clinical practice, research investment, accreditation, and specialised capability into a single public address — deserve stable, findable, durable identity. The onchain namespace rbwh.queensland represents precisely that: a permanent civic identifier for an institution whose function is not transient, whose mandate does not expire with any government term, and whose presence in Herston has been continuous for well over a century. As Queensland grows, as cancer rates evolve with demographics and climate, and as clinical capabilities shift with research advances, the need for a stable institutional anchor — one that persists across administrative changes, infrastructure upgrades, and generations of patients — becomes only more, not less, pressing. That permanence is what a civic identity layer exists to provide.